2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4581 Survival outcomes and therapeutic response among US patients with acute myeloid leukemia from second line-therapy (LOT2) by fitness status

Tara Beaulieu, PhD, MIPH, Xiaojian Chen2, Laura Hester, PhD, MSc3, Kathryn Bradford, MD4, Dina Gifkins, PhD, MPH5
1 Johnson & Johnson, Raritan, New Jersey, United States
2 Johnson & Johnson, Potomac, Maryland, United States
3 Johnson & Johnson, Horsham, Pennsylvania, United States
4 Johnson & Johnson, Spring House, Pennsylvania, United States
5 Johnson & Johnson, Raritan, New Jersey, United States

Background: There is limited published research on therapeutic response and survival outcomes among subpopulations with acute myeloid leukemia (AML), after initiating the second-line therapy (LOT2). This study evaluated complete response (CR) following LOT2 and 5-year overall survival (OS) by fitness status and response to first-line therapy (LOT1).

Methods: Patients with newly diagnosed AML from 2018-2025 were identified from the COTA/Verana Vantage AML, which includes structured and unstructured electronic health records from United States (US) oncology clinics. Fitness status was approximated using a published proxy with fit defined as an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and age <78 years; and unfit as an ECOG performance status score of 2-4 (any age) or age ≥78 years. National Comprehensive Cancer Network (NCCN) guidelines were used to develop a line of therapy algorithm for AML. CR following patients initiating LOT2 from 2018-2025 was defined as achieving: CR, morphologic CR, molecular CR, cytogenetic CR, CR with partial hematologic recovery. No evidence of having achieved CR was defined as: CR with incomplete blood cell count recovery, induction failure, near CR, morphologic leukemia free state, partial response, near CR, no response, stable disease, persistent disease, progression relapse, very good partial response, and missing. Five-year OS was calculated using Kaplan-Meier analysis with 95% confidence intervals (CI) among patients initiating LOT2 who achieved CR or had no evidence of achieving CR to LOT1 by fitness status.

Results: Among 883 initiating LOT2 (2018-2025) for AML in the COTA/Verana database, 660 (75%) had fitness status data. Regardless of fit status, 38% achieved CR to LOT2, and 62% had no evidence of achieving CR to LOT2. Survival cohorts included fit patients who achieved CR to LOT1 (n=270), fit patients who did not achieve CR to LOT1 (n=230), unfit patients who achieved CR to LOT1 (n=65), and unfit patients who did not achieve CR to LOT1 (n=95). Five-year OS was 23% (95% CI: 18%-31%) among fit patients who achieved CR to LOT1, and 24% (95% CI: 19%-32%) among fit patients who had no evidence of achieving CR to LOT1. Notably, these OS findings could be similar as these cohorts were conditioned on having reached LOT2. Five-year OS was considerably lower among unfit patients that achieved CR to LOT1, and among unfit patients that had no evidence of achieving CR to LOT1 (8% [95% CI: 3%-22%] and 9% [95% CI: 4%-18%], respectively).

Conclusion: These findings suggest that US AML patients unfit for intensive treatment may experience less favorable 5-year OS relative to patients fit for intensive treatment, and that most patients who initiated LOT2 had no evidence of achieving CR. These results highlight a pressing need to determine optimal therapeutic approaches for patients unfit for intensive therapy and, an opportunity to further advance innovative treatments for patients with relapsed or refractory disease.

Tara Beaulieu, PhD, MIPH: Johnson & Johnson - Current equity holder in publicly-traded company; Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment